S*BIO's HDAC inhibitor moves forward for prostate cancer
This article was originally published in Scrip
Executive Summary
As it said it would earlier this year, S*BIO has begun a Phase II clinical trial by the end of the third quarter for its lead oral histone deacetylase (HDAC) inhibitor, SB939, for the treatment of recurrent or metastatic prostate cancer.